市场调查报告书
商品编码
1394977
细胞解离市场规模 - 按产品(酵素解、非酵素解)、应用(组织解离、细胞分离)、最终用户、全球预测,2023 - 2032 年Cell Dissociation Market Size - By Product (Enzymatic Dissociation, Non-Enzymatic Dissociation), Application (Tissue Dissociation, Cell Detachment), End-user, Global Forecast, 2023 - 2032 |
预计从 2023 年到 2032 年,细胞解离市场规模的CAGR将达到 15.3%。对细胞疗法和再生医学的需求不断增长,推动了对多种有效细胞解离方法的需求。最近,研发活动不断取得进步,特别是在干细胞研究和生物技术方面。
慢性病盛行率的上升和对个人化医疗的需求不断增长将推动对用于治疗目的的分离细胞的需求。此外,实验室技术和技术的不断发展以及生命科学研究投资的不断增加也将推动更有效的解离方法开发的创新。例如,2022年3月,LevitasBio推出了LeviPrep(TM)和LeviSelect(TM)产品线,以增强人类和小鼠组织和细胞样本的处理,以进行高级生物研究。
细胞分离市场分为产品、应用、最终用户和地区。
根据产品,预计 2023 年至 2032 年非酶解领域的行业份额将达到 16.2% 的CAGR。这一增长可归因于对温和高效解离方法的需求不断增加、细胞压力减少以及对敏感细胞类型。非酵素方法也因其与各种细胞培养应用和工作流程的兼容性而受到重视。
细胞分离应用领域预计将占据相当大的收入份额,在整个分析期间CAGR为 16.5%。这是由于细胞培养过程中对高效且可重复的分离方法的需求不断增长。生物技术、再生医学和细胞疗法的应用不断增加将促进该领域的成长。
从地区来看,欧洲细胞解离产业规模预计从 2023 年到 2032 年将快速成长。这种成长可归因于细胞研究的不断进步、生物技术应用范围的扩大以及生命科学研究的大量资金。此外,一些欧洲国家对创新医疗解决方案的日益关注以及对个人化医疗的高需求将推动该地区对细胞分离技术的需求。
Cell dissociation market size is projected to record 15.3% CAGR from 2023 to 2032. The increasing demand for cell-based therapies and regenerative medicine is driving the need for several efficient cell dissociation methods. Of late, there have been rising advancements in R&D activities, particularly in stem cell research and biotechnology.
The rising prevalence of chronic diseases and the growing need for personalized medicine will drive the demand for dissociated cells for therapeutic purposes. Additionally, the continuous evolution of laboratory techniques and technologies along with the growing investments in life sciences research will also push innovations in the development of more effective dissociation methods. For instance, in March 2022, LevitasBio introduced the LeviPrep™ and LeviSelect™ product lines to enhance the processing of human and mouse tissue and cell samples for advanced biological research.
The cell dissociation market is segregated into product, application, end-user, and region.
Based on product, the industry share from the non-enzymatic dissociation segment is projected to depict 16.2% CAGR from 2023 to 2032. The growth can be attributed to the increasing demand for gentle and efficient dissociation methods, reduced cell stress, and the suitability for sensitive cell types. The non-enzymatic approach is also gaining prominence for its compatibility with various cell culture applications and workflows.
The cell detachment application segment is estimated to account for sizeable revenue share, exhibiting 16.5% CAGR throughout the analysis period. This is owing to the rising demand for efficient and reproducible detachment methods in cell culture processes. The increasing application in biotechnology, regenerative medicine, and cell-based therapies will boost the segment growth.
Regionally, the Europe cell dissociation industry size is slated to grow at rapid pace from 2023 to 2032. The growth can be ascribed to the increasing advancements in cell-based research, expanding application scope in biotechnology, and hefty funding for life sciences research. Additionally, the rising focus of several European countries on innovative healthcare solutions along with the high demand for personalized medicine will fuel the demand for cell dissociation technologies in the region.